Hydration Proper hydration supports skin elasticity and function
GIP (Glucose-Dependent Insulinotropic Polypeptide) This is also activated by: Mounjaro (tirzepatide) GIP appears to: improve insulin sensitivity enhance satiety alongside GLP-1 reduce body fat improve glucose control make weight loss more sustainable Researchers believe GIP helps reduce some of the gastrointestinal side effects often experienced with GLP-1 medicines, although this continues to be investigated
Due to these findings, oral Wegovy would currently be my preferred choice when cardiovascular risk reduction is top priority, says Anton, noting that both medications seem promising for people focused primarily on blood glucose control or creating modest improvements in blood pressure and cholesterol
Unfortunately, certain medications and treatments can actually aggravate symptoms instead of offering relief
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from the cerebral venous blood of sleep-deprived rabbits

Higher dose exploration (4.5mg trials) Rationale for testing 4.5mg: Investigate maximum tolerable dose Determine if higher = better weight loss Establish safety ceiling Results at 4.5mg weekly: Weight loss: ~12% (vs 10% at 2.4mg) Incremental benefit: Only 2% additional loss Side effects: Significantly worse nausea/vomiting Dropout rate: Higher than 2.4mg Clinical verdict: 4.5mg not recommended for routine use Risk-benefit ratio unfavorable 2.4mg remains optimal Some individuals may tolerate 3.0mg as compromise CagriSema combination dosing trials REDEFINE-1 protocol: Semaglutide: 2.4mg weekly (standard titration over 16 weeks) Cagrilintide: 2.4mg weekly (12-week titration) Both given as separate injections Started simultaneously from week 1 Semaglutide escalation (standard): Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17+: 2.4mg Cagrilintide escalation (when combined): Weeks 1-4: 0.6mg Weeks 5-8: 1.2mg Weeks 9-12: 1.8mg Week 13+: 2.4mg Results: 15.6% average weight loss (68 weeks) Superior to either alone Side effects manageable with slow titration Combination well-tolerated See our cagrilintide and semaglutide combination guide and semaglutide dosage calculator
